[HTML][HTML] Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MAS Elgohary, EM Hasan, AA Ibrahim… - Journal of Medicine …, 2022 - ncbi.nlm.nih.gov
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
[PDF][PDF] Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MG Seadawy - JOURNAL of MEDICINE and LIFE, 2022 - medandlife.org
ABSTRACT COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MAS Elgohary, EM Hasan, AA Ibrahim… - 2022 - pubmed.ncbi.nlm.nih.gov
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial
MAS Elgohary, EM Hasan, AA Ibrahim, MF Ahmed… - 2021 - pesquisa.bvsalud.org
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard
treatment: Randomized controlled trial | PREPRINT-MEDRXIV loading 1 2 3 +A A -A 3.Efficacy …
treatment: Randomized controlled trial | PREPRINT-MEDRXIV loading 1 2 3 +A A -A 3.Efficacy …
[PDF][PDF] Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MG Seadawy - JOURNAL of MEDICINE and LIFE, 2022 - scienceopen.com
ABSTRACT COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
MAS Elgohary, EM Hasan, AA Ibrahim… - … of Medicine & Life, 2022 - search.ebscohost.com
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MAS Elgohary, EM Hasan, AA Ibrahim… - Journal of Medicine …, 2022 - search.proquest.com
ABSTRACT COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial
MAS Elgohary, EM Hasan, AA Ibrahim… - medRxiv, 2021 - medrxiv.org
Background COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by …
virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by …
[HTML][HTML] Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial
MA Elgohary, EM Hasan, AA Ibrahim, AA MF… - 2021 - europepmc.org
Background COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by …
virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by …
[PDF][PDF] Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
MG Seadawy - JOURNAL of MEDICINE and LIFE, 2022 - medandlife.org
ABSTRACT COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …
virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is …